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Psoriasis is a chronic inflammatory skin disease with 
profound effects on patients’ health-related quality of 
life (HRQoL). Twenty-nine patients with plaque psoria-
sis and a history of streptococcal-associated psoriasis 
exacerbations were randomly assigned to tonsillecto-
my (n = 15) or control (n = 14) groups and followed for 
24 months. Patients were evaluated with the Psoriasis 
Disability Index, Psoriasis Life Stress Inventory and 
Psoriasis Area and Severity Index. HRQoL and psoria-
sis-related stress improved significantly in the tonsillec-
tomy group compared with the control group (p = 0.037 
and p = 0.002, respectively), with a mean 50% improve-
ment in HRQoL and a mean 59% improvement in pso-
riasis-induced stress. Clinical improvement correlated 
significantly with improved HRQoL (r = 0.297, p = 0.008) 
and psoriasis-related stress (r = 0.310, p = 0.005). Of 
the tonsillectomized patients, 87% concluded that the 
procedure was worthwhile. Tonsillectomy may improve 
quality of life for selected patients with plaque psoriasis.
Key words: chronic plaque psoriasis; streptococcal throat in-
fection; tonsillectomy; health-related quality of life; Psoriasis 
Disability Index; Psoriasis Life Stress Inventory. 
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Psoriasis is a complex multifactorial disease caused by a combination of genetic and environmental factors 
(1), affecting approximately 2–3% of the world’s popu-
lation (2). Psoriasis has a significant negative impact on 
many areas of health-related quality of life (HRQoL), 
including physical, occupational, social, psychological, 
and sexual wellbeing (3–5). Patients with psoriasis have 
reduced HRQoL, similar to that caused by major chronic 
illnesses such as cancer, myocardial infarction and dia-
betes mellitus (6). Many patients have low self-esteem 
and feel embarrassed, helpless, and stigmatized due to the 
visible nature of psoriasis (7, 8), which causes  significant 
daily stress for patients (9). Clinical assessments, such as 
the Psoriasis Area and Severity Index (PASI) (10), do not 
adequately reflect the general impact that the disease has 
on the lives of patients with psoriasis, but instead give a 
static score of clinical disease severity (11). 
Many environmental factors have been implicated in 
psoriasis; in particular, throat infection with β-haemolytic 
streptococci has been associated with both the initiation 
and exacerbation of psoriasis (12–15). T cells primed 
by streptococcal antigens in the tonsils may react with 
homologous antigens in the skin (16–18), and there 
are several reports of partial or complete remission of 
psoriasis after tonsillectomy (reviewed by (19–21)). We 
reported previously on a randomized controlled trial exa-
mining the clinical efficacy and immunological impact of 
tonsillectomy on plaque psoriasis. The results indicated 
that tonsillectomy can lead to a significant clinical impro-
vement in plaque psoriasis, with a significant reduction 
in the frequency of skin-homing T cells that recognize 
homologous streptococcal M-protein and skin keratins 
(22). We report here findings related to patient HRQoL 
and psoriasis-induced stress and their association with 
clinical improvement after tonsillectomy. 
METHODS
Patients
Patient eligibility criteria have been detailed previously (22). 
Briefly, eligible patients were: ≥ 18 years of age; had moderate-
to-severe chronic plaque psoriasis diagnosed by a dermatologist; 
had a history of sore throat-associated psoriasis exacerbation; and 
were willing to undergo tonsillectomy. Exclusion criteria were: 
underlying medical conditions, such as heart and lung diseases 
and bleeding disorders; alcohol or drug abuse; pregnancy; and 
previous tonsillectomy. Before study initiation patients were re-
quired to discontinue all psoriasis treatment except moisturizers 
within the previous 4 weeks.
Fifty-four patients were screened for the study, the majority of 
whom were referred by a dermatologist (44%) or responded to an 
advertisement (46%). A few patients had heard about the study by 
other means (6%) or were referred by an otolaryngologist (4%). 
Written informed consent was obtained from each patient before 
initiation of study participation. A total of 29 patients met the 
inclusion criteria.
Study design
This was a single-centre, 24-month, parallel, assessor-blind, 
randomized controlled trial. Data were collected within the de-
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partments of Dermatology and Otolaryngology-Head and Neck 
Surgery in Landspitali, The National University Hospital of Ice-
land, Reykjavik, Iceland, from November 2007 to January 2011. 
The study was conducted in accordance with the 1964 Declaration 
of Helsinki and its later amendments and approved by the National 
Bioethics Committee of Iceland (VSNb2006090015/03-15) and 
the Data Protection Authority of Iceland. 
A sealed allocation sequence with a numerical code was created 
by the study supervisor before recruitment began, with a simple 
randomization in a 1:1 ratio. The 29 patients who met the inclusion 
criteria were allocated into tonsillectomy and control groups (Fig. 
1). The allocation was concealed until the end of the study in order 
to reduce study bias. Recruitment and follow-up of all patients was 
performed by the same investigator throughout the study, who was 
unaware of the allocation system and thus the tonsil status of the 
patients. Detailed data were collected on patients’ demographics 
and psoriasis features. Patient-reported outcomes were measured 
at baseline and at months 12 and 24.
Study end-points
Primary end-points were defined as clinically significant changes 
in HRQoL, assessed by the Psoriasis Disability Index (PDI) and 
Psoriasis Life Stress Inventory (PLSI) at 12 and 24 months. These 
parameters, along with secondary end-points, were compared with 
baseline scores and between the 2 groups. Secondary end-points 
included the correlations between the change in clinical disease 
severity (Psoriasis Area and Severity Index, PASI score) and 
HRQoL scores (PDI and PLSI) as well as evaluation of a study-
specific questionnaire, applied at the end of the study. 
Questionnaires
HRQoL was assessed with a psoriasis-specific questionnaire, 
the Psoriasis Disability Index (PDI) (23). The PDI is a validated 
self-administered questionnaire covering aspects of functional 
disability owing to psoriasis in the preceding 4 weeks. The PDI 
addresses 15 issues that can group to 5 domains: daily activities, 
work/school, personal relationships, leisure, and treatment. The 
PDI score is rated on a 4-point scale, with grades from “not at 
all” to “very much” and the total score, ranging from 0 to 45, is 
calculated by summing the scores given to each question. The 
total score can therefore range from none to maximal impairment 
of quality of life. 
Psoriasis-related stress was assessed with the Psoriasis Life 
Stress Inventory (PLSI) (24). The PLSI is a 15-item questionnaire 
that estimates psychosocial stress due to psoriasis. For each ques-
tion the patients must rate the level of stress experienced over the 
previous 4 weeks on a 4-point scale, ranging from “not at all” to 
“very much.” The PLSI score, ranging from 0 to 45, is calculated 
by summing the scores for each question. Both the PDI and PLSI 
have been used in the English version for evaluation of psoriasis. 
The questions were translated into Icelandic using the translation-
back-translation procedure and validated by the Nordic Quality 
of Life study (25). The patients completed both questionnaire at 
study entry and at 12 and 24 months.
After the 24-month study period, participants answered a 
study-specific questionnaire with the aim of rating the overall 
experience of having tonsillectomy as a treatment for psoriasis. 
The questionnaire was composed of 20 multiple-choice questions, 
rated on a scale ranging from “not at all” to “very much” and 3 
short-answer questions. The questions addressed difficulties as-
sociated with the tonsillectomy, recovery time, complications, 
and whether the operation had been worthwhile. Also, questions 
about self-perceived improvement in psoriasis, psoriasis nails and/
or psoriatic arthritis and regarding HRQoL and psoriasis stress. 
Moreover, participants were asked about the use of psoriasis 
treatments, such as moisturizers, topical treatments or systemic 
therapy, and if they had experienced sore throat or streptococcal 
throat infections with subsequent exacerbation of psoriasis after 
removal of their tonsils. 
Clinical evaluation
Clinical follow-up has been detailed previously (22). Briefly, 
clinical severity was assessed by PASI score (10) at study entry 
and at 2, 6, 12, 18 and 24 months. The use of psoriasis treatment 
agents during the follow-up period was monitored closely. 
Statistical analysis
Patient demographics were summarized descriptively and data 
were tested for normality using the Kolmogorov-Smirnov test. 
PDI and PLSI scores at months 12 and 24 were compared between 
the groups and with baseline scores using analysis of variance 
(ANOVA) test for repeated measurements. Data for months 12 
and 24 were analysed with the intent-to-treat method, where any 
missing data were replaced using the last observation carried for-
ward (LOCF) method. Square root transformation of the results 






Men, n (%) 3 (20) 6 (43)
Age, years, mean ± SD 35.3 ± 9.9 35.9 ± 9.8
BMI (kg/m2) mean ± SD 25.2 ± 5.3 25.4 ± 3.6
Smokers, n (%) 4 (27) 6 (43)
Age at psoriasis onset, years, mean ± SD 15 ± 7.9 15 ± 7.1
Sore throat psoriasis onset, n (%) 3 (20) 2 (14)
Duration of psoriasis, years, mean ± SD 19.9 ± 9.5 20.5 ± 11.7
Psoriasis family history, n (%) 12 (80) 12 (86)
Psoriatic arthritis, n (%) 4 (27) 1 (7)
PASI score, mean ± SD 11.0 ± 5.7 9.3 ± 3.7
PDI score, mean ± SD 10.4 ± 7.1 9.3 ± 7.3
PLSI score, mean ± SD 12.0 ± 6.1 10.0 ± 7.0
Previous treatments, n (%)
Topical agents 8 (53) 8 (57)
Phototherapy 5 (33) 4 (29)
Systemic therapy 1 (7) 0
SD: standard deviation; BMI: body mass index, PASI: Psoriasis Area and Severity 
Index, PDI: Psoriasis Disability Index, PLSI: Psoriasis Life Stress Inventory.
Fig. 1. CONSORT (Consolidated Standards of Reporting Trials) 
flow diagram.
54 screened for eligibility
Excluded (n = 25)
  Did not meet inclusion criteria (n = 16)
  Declined participation (n = 3)
  Excluded for other reasons (n = 6)
29 randomized
Allocated to tonsillectomy (n = 15)
Discontinued (n = 1):
  Received methotrexate for psoriatic
  arthritis after 12 months
14 completed the 24-month follow-up
Allocated to control group (n = 14)
Discontinued (n = 2):
  Lymphoma after 12 months
  Tonsillectomy after 18 months
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was used to better approximate normality in the ANOVA model. 
Statistical significance was defined by p < 0.05. Spearman’s rank 
correlation analysis was performed to evaluate the relationships 
between clinical improvement and improvement in HRQoL (PDI 
and PLSI scores) from baseline to month 24. Data analyses were 
performed using R software, version 2.10 (The R foundation, 
Austria).
RESULTS
Of the 54 patients with psoriasis who were screened, 
38 met all the inclusion criteria. Six eligible patients 
were excluded due to chronic disease, ongoing systemic 
psoriasis treatment and pregnancy, and 3 declined to par-
ticipate after screening. Thus, a total of 29 patients with 
plaque psoriasis and a history of psoriasis exacerbation 
during or after a sore throat were enrolled in the study 
(Fig. 1). Fourteen patients in the tonsillectomy group 
and 12 in the control group completed the 24-month 
follow-up, which took place from November 2008 to 
January 2011. One patient in the tonsillectomy group was 
started on methotrexate to treat his psoriatic arthritis after 
12 months of participation. Two patients in the control 
group did not complete the study, one was diagnosed 
with lymphoma after 12 months, and the other violated 
the protocol by having tonsillectomy after 18 months of 
follow-up. There were no clinically meaningful differen-
ces between the groups and, although the tonsillectomy 
group had slightly higher baseline PASI, PDI and PLSI 
scores compared with the control group, these differences 
were not statistically significant (Table I). 
There was a significant improvement in HRQoL 
after tonsillectomy (Fig. 2A). The mean PDI score de-
creased significantly in the tonsillectomized group, both 
with time (p = 0.026) and compared with the controls 
(p = 0.037, 95% confidence interval (CI), 1.43–3.58). 
The patients’ quality of life improved in mean by 50%. 
In accordance with a report (26), we divided the PDI 
data into 5 domains, to identify the areas that were most 
influenced by the tonsillectomy (Table II). There were 
significant changes in HRQoL associated with work and/
or school after 12 and 24 months (p = 0.02 and p = 0.022, 
respectively) compared with the control group. The 
change in HRQoL associated with relationships was 
significant after 12 months (p = 0.04) and the change 
in HRQoL linked to the treatments was significant at 
24 months (p = 0.04). No corresponding improvement 
in PDI scores (p = 0.803, 95% CI 3.38–4.23) or PDI 
domains was observed in the control group. 
The tonsillectomized patients reported that their stress 
associated with having psoriasis decreased considerably 
after the tonsillectomy (Fig. 2B). Their PLSI score de-
creased significantly both with time (p < 0.001) and com-
pared with the controls (p = 0.002, 95% CI 1.39–3.10), 
and improved, in mean by 59%. The control group did 
not exhibit any significant improvement in psychosocial 
stress related to coping with psoriasis (p = 0.654, 95% 
CI 2.67–3.56).
A significant positive correlation was observed 
between clinical improvement and increased HRQoL 
(r = 0.297, p = 0.008) (Fig. 3A). Likewise, there was a 
Fig. 2. Changes in health-related quality of life 
(HRQoL) and psoriasis-induced stress of the 29 
participating psoriasis patients during the 24-month 
follow-up. Panel A: Tonsillectomized patients reported 
an improvement in HRQoL with a significant decrease 
in the mean Psoriasis Disability Index (PDI) score, both 
with time (p=0.026) and compared with the controls 
(p = 0.037, 95% confidence interval (CI) 1.43–3.58). 
No corresponding changes were observed for the control 
group. Panel B: Tonsillectomized patients reported less 
daily stress associated with their psoriasis, which was 
reflected in significantly decreased Psoriasis Life Stress 
Inventory (PLSI) score, both with time (p < 0.001) and 
compared with the controls (p = 0.002, 95% CI 1.39–3.10). 
The control group observed no corresponding changes. 

















































Table II. Mean changes in domains of the Psoriasis Disability Index (PDI) before and after tonsillectomy of the 29 participating patients 
with psoriasis
 








Mean ± SD p-value
Daily activity 1.53 ± 3.18 0.29 ± 1.20 ns 1.79 ± 2.91 0.18 ± 2.89 ns
Work/school 1.00 ± 1.56 –0.07 ± 0.47 0.02 0.86 ± 1.66 –0.64 ± 1.29 0.02
Relationships 1.13 ± 1.96 0.07 ± 0.27 0.04 0.71 ± 1.98 –0.27 ± 1.10 ns
Leisure 1.07 ± 1.91 0.00 ± 0.88 ns 1.07 ± 2.13 0.27 ± 1.19 ns
Treatment 0.60 ± 1.06 0.07 ± 0.92 ns 1.00 ± 1.11 0.09 ± 0.94 0.04
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significant positive correlation between improvement 
in PASI score and improved psoriasis-related stress 
(r = 0.310, p = 0.005) (Fig. 3B).
At the end of the study, all the patients who had tonsil-
lectomy answered a short, study-specific, questionnaire. 
Twelve (80%) patients felt that the surgery had been quite 
difficult and that the recovery took more time than they 
had expected. No major post-operative complications 
were reported, but one patient had minor bleeding the 
day after the procedure. Nevertheless, 13 (87%) of the 
patients thought that the surgery was worthwhile and 
12 (80%) concluded that their psoriasis had improved 
markedly after the surgery. Two patients did not think 
that there was any clinical difference regarding psoriasis 
symptoms and one was unsure. When asked about the 
use of moisturizers, topical treatments and other psoriasis 
treatments during the 2 years after the tonsillectomy 12 
(80%) patients reported less or fewer psoriasis treat-
ments after the surgery. One out of 4 patients who had 
concomitant psoriasis arthritis reported an improvement 
in arthritis after the tonsillectomy.
DISCUSSION 
We and others (22, 27, 28) have previously reported that 
tonsillectomy can have marked clinical benefits for selec-
ted patients with psoriasis. We now extend these findings 
to demonstrate that the improvement in clinical activity 
of psoriasis achieved through tonsillectomy, despite 
being an overall difficult procedure to go through, leads 
to a significant positive impact on the activities of daily 
life and psychosocial wellbeing of patients. Thus, the 
HRQoL improved by 50% and tonsillectomized patients 
reported almost 60% lower psoriasis-related stress after 
the surgery. Furthermore, we found that the increased 
HRQoL and improved psoriasis-related stress correlated 
positively with the observed clinical improvement, as 
assessed by PASI scores. 
Patients with psoriasis have a 10-fold higher frequency 
of symptomatic streptococcal throat infections than 
matched household controls (14), and the asymptomatic 
carrier rate for group A, C and G Streptococci has been 
reported to be as high as 44% in patients with plaque 
psoriasis and a known history of psoriasis exacerbation 
associated with sore throat (29). Furthermore, up to 70% 
of Icelandic patients with plaque psoriasis report an 
exacerbation of psoriasis symptoms during streptococcal 
throat infections (30). Thus, the genetic background of 
patients with psoriasis appears to be permissive for both 
streptococcal carriage and symptomatic streptococcal 
throat infections, and the latter has long been associated 
with flares of guttate psoriasis (12, 15, 31) as well as wor-
sening of chronic plaque psoriasis (13, 14). It would be of 
interest to measure antistreptolysin O (ASO) titres (32) 
in patients who have tonsillectomy and correlate titres 
with both clinical improvement and increased HRQoL. 
We have recently reported that patients who benefit most 
from tonsillectomy, both clinically and in terms of quality 
of life, significantly more often have psoriasis onset asso-
ciated with a throat infection. Furthermore, these patients 
reported an increased frequency of streptococcal throat 
infections per lifetime and were carriers of both copies 
of HLA-Cw*0602 (33). The mechanism whereby HLA-
Cw*0602 predisposes to psoriasis is currently unknown. 
Our data, and those of others (17, 34–37), are consistent 
with the hypothesis that autoantigens presented in the 
binding pockets of HLA-Cw*0602 on epidermal cells are 
recognized by CD8+ T lymphocytes infiltrating lesional 
epidermis (18). 
Although not yet validated, our end-of-study ques-
tionnaire gave an insight to the experience of having 
tonsillectomy to treat plaque psoriasis. Despite the risk of 
having the surgery, risk of post-operative complications 
and prolonged recovery time, 87% of the patients thought 
that the procedure was worthwhile, and 80% reported 
a marked improvement, which is concordant with the 
Fig. 3. Correlation between clinical improvement, improved health-related quality of life (HRQoL) and psoriasis-related stress of the 15 
tonsillectomized patients with psoriasis during the 24-month follow-up. Panel A: A significant positive correlation was noted between the change 
in clinical status (PASI score) and change in health-related quality of life (PDI score) (r = 0.297, p = 0.008). Panel B: Likewise, there was a significant 
positive correlation between the change in clinical status and the change in psoriasis-related stress (PLSI score) (r = 0.310, p = 0.005). Spearman’s rank 
correlation test. PASI: Psoriasis Area and Severity Index, PDI: Psoriasis Disability Index, PLSI: Psoriasis Life Stress Inventory.
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recorded reduction in PASI scores, ranging from 30% to 
90%, in 87% of patients (22). Furthermore, 80% of the 
patients reported that their need for psoriasis treatment 
in the form of moisturizers, topical treatments, ultravio-
let light treatment or other treatments was noticeably 
less after the tonsillectomy. This is in accordance with 
our previous finding that patients with plaque psoriasis 
needed less symptomatic treatment after tonsillectomy 
compared with controls (22). 
One out of the 4 patients with concomitant plaque 
psoriasis and psoriatic arthritis (PsA) reported at the 
end of the study that his arthritis had improved after the 
tonsillectomy. Interestingly, this patient was homozygous 
for HLA-Cw*0602, which is strongly associated with cu-
taneous psoriasis (38, 39), early onset psoriasis (40–42), 
and psoriasis exacerbations after streptococcal throat 
infection (43, 44). There are very few studies that have 
explored a possible link between PsA, the tonsils and 
streptococcal throat infections. DNA encoding the 16S 
ribosomal RNA gene of group A streptococci has been 
found in the blood and synovial fluid of patients with PsA 
(45), and synovial T cells from patients with PsA have 
been reported to respond to streptococcal superantigens, 
but not to conventional streptococcal antigens (46).
There is currently no cure for psoriasis, and available 
treatments only offer symptomatic relief, as psoriasis 
typically relapses when treatments are discontinued. 
Our results suggest that selected patients with plaque 
psoriasis and a history of sore throat-associated exacerba-
tion could benefit from tonsillectomy, both with respect 
to clinical measures of disease severity (PASI) as well 
as improved quality of life and reduced disease-related 
stress. Although our patient cohort was followed for 
only 2 years, we have observed that the improvement 
remains at least 5 years post-tonsillectomy (unpublished 
data). We therefore conclude that tonsillectomy may be 
a significant addition to the current psoriasis treatment 
for a selected patient group, and offer a long-lasting 
improvement. However, more robust trials and long-
term follow-up of tonsillectomized patients with plaque 
psoriasis are needed. 
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